ArticleStroke2026
Myeloid Cell-Specific Retinoid X Receptor Signaling Facilitates White Matter Repair and Stroke Recovery in Aged Mice.
Article in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAs stroke is the leading cause of long-term disability in the elderly, effective pharmacological therapies for neurorestoration remain an unmet clinical need. RXR (retinoid X receptor) signaling regulates inflammation and tissue repair, but the downstream repair processes linking RXR activation to stroke recovery in the aged central nervous system remain incompletely defined. We used aged mice to test the hypotheses that (1) pharmacological RXR stimulation with the brain-penetrant pan-RXR agonist bexarotene boosts poststroke recovery and (2) myeloid cell-specific RXR signaling facilitates white matter repair and underlies the therapeutic effects of bexarotene.
methodsPermanent focal cerebral ischemia was induced in 18- to 22-month-old C57BL/6J male and female mice by distal middle cerebral artery occlusion. Pharmacological RXR activation and genetic ablation were achieved by poststroke bexarotene administration and generation of myeloid cell-specific RXR conditional knockout mice, respectively. Functional (sensorimotor and cognitive performance) and structural measures of central nervous system recovery were assessed up to 35 days after stroke.
resultsPoststroke treatment with bexarotene (5-10 mg/kg) improved sensorimotor performance in the rotarod, foot fault, and adhesive removal tests and alleviated cognitive deficits in the Morris water maze and passive avoidance tests. Bexarotene improved white matter integrity at 35 days after distal middle cerebral artery occlusion, without impacting white matter at 3 days or preventing gray matter atrophy at chronic injury stages. Bexarotene also suppressed immune cell infiltration and proinflammatory cytokine production, enhanced inflammation-resolving efferocytosis, promoted long-term oligodendrogenesis and angiogenesis, and fostered a prorepair central nervous system microenvironment. Accordingly, stroke outcomes were markedly worsened in aged RXR conditional knockout mice compared with age-matched wild-type mice, and the functional and white matter benefits of bexarotene were blocked in RXR conditional knockout mice.
conclusionsMyeloid RXR signaling promotes long-term stroke recovery in aged mice of both sexes and engages anti-inflammatory and prorepair mechanisms. Bexarotene warrants further evaluation as a potential neurorestorative therapy for stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.